Aspen approved for secondary listing on A2X
The complementary A2X listing offers investors trading benefits, says Aspen Group CEO Stephen Saad.
Aspen Pharmacare Holdings Ltd has been approved for a secondary listing on A2X Markets and will list on 1 April 2019.
Aspen Group CEO Stephen Saad (pictured) said:
“We continually strive to identify ways to increase value for our shareholders and the complementary A2X listing offers investors trading benefits while simultaneously providing the prospect of increasing our shareholder base. We will retain our primary listing on the Johannesburg Stock Exchange and our issued share capital will be unaffected by the secondary listing.”
The leading specialty and branded multinational pharmaceutical company will retain its primary listing on the JSE and its issued share capital will be unaffected by the secondary listing.
A2X CEO Kevin Brady also commented:
“A2X is thrilled to have South Africa’s largest pharmaceutical company on board. No doubt that Aspen will reap the benefits of a secondary listing, including the opportunity to attract potential new investors through A2X’s lower-cost trading structure and broadening their shareholder base."